What is ATNM's market cap?

$44.65M, based on the Nov 4 close of $1.42.

What is ATNM's P/E ratio?

3.9× trailing-twelve-month earnings of $11.31M.

Does Actinium Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ATNM is sold short?

631.2K shares, 2.0% of float, as of Oct 15, 2026.

What sector is ATNM in?

Healthcare, in the Pharmaceuticals industry.

NYSE American · ATNMHealthcarePharmaceuticals

Actinium Pharmaceuticals, Inc (ATNM)

$1.42+1.43%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.41▲ 4.44% in range

Nov 4, 2025Low $0.75 · High $1.69Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Actinium Pharmaceuticals closed at $1.42 on Nov 4, up 1.43%, 16.0% below its 52-week closing high. Volume of 85.3K shares was 0.36× its 20-day average (below normal).

Split-adjusted performance: +27.9% over one month, +14.5% over six months, +2.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $35M, with a net margin of 79.7%.

Short interest was 631.2K shares at the Oct 15 settlement, down 10.6% from the prior report (2.0% of float, 4.8 days to cover).

Market cap$44.6M31.4M shares

Revenue · quarter$35.0M—

Diluted EPS$0.89—

P/E · TTM3.9×P/S 1.3×

Net margin79.7%Gross 100.0%

Dividend yieldNone

52-week range0.75 – 1.69−16.0% from high

Volume85.3K0.36× 20-day avg

Volatility · 60d90.5%Annualised

Short % of float2.0%4.8 days to cover

Net cash$36.5MCash $36.5M

Next earnings—Not scheduled

Split-adjusted performance

1W +2.9%1M +27.9%3M +80.4%6M +14.5%YTD +4.4%1Y +2.9%3Y −74.5%5Y −81.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum79

Revenue growth—

Net margin97

Value (low P/E)90

Size29

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short631.2K−10.6% vs prior

Days to cover4.8Settled Oct 15

% of float2.0%

Short vol. 10d33.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ATNMActinium Pharmaceuticals	$1.42	+1.43%	+14.5%	—	79.7%	3.9	$44.6M
BMEABiomea Fusion	$0.6296	+0.93%	−60.6%	—	—	—	$45.6M	Compare
SERSerina Therapeutics	$1.70	−7.10%	−7.1%	−100.0%	—	—	$43.2M	Compare
HYPDHyperion DeFi	$3.12	+2.13%	−14.4%	—	4009.1%	—	$47.4M	Compare
ELTXElicio Therapeutics	$1.55	+1.97%	−85.2%	—	—	—	$42.0M	Compare
GANXGain Therapeutics	$1.14	−1.30%	−40.6%	—	—	—	$49.5M	Compare
CNTBConnect Biopharma Holdings Limited	$0.7887	+1.89%	−68.2%	+5666.7%	−624.4%	—	$49.7M	Compare
DWTXDogwood Therapeutics	$1.04	0.00%	−37.0%	—	—	—	$39.8M	Compare
ALDXAldeyra Therapeutics	$0.6502	+4.77%	−62.6%	—	—	—	$39.2M	Compare

News about Actinium Pharmaceuticals

All news →

No recent articles focused on Actinium Pharmaceuticals. 2 articles mention it in passing.

Quick answers

What does Actinium Pharmaceuticals do?: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia.
What is ATNM's market cap?: $44.65M, based on the Nov 4 close of $1.42.
What is ATNM's P/E ratio?: 3.9× trailing-twelve-month earnings of $11.31M.
Does Actinium Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ATNM is sold short?: 631.2K shares, 2.0% of float, as of Oct 15, 2026.
What sector is ATNM in?: Healthcare, in the Pharmaceuticals industry.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

HQ: New York, NY25 employeesListed Jul 19, 2007actiniumpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology